Search
Dexamethasone Treatment Options
A collection of 1455 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
469 - 480 of 1455
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Active Not Recruiting
This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone. The purpose of this study is to test whether giving daratumumab along with the other drugs (carfilzomib, lenalidomide and dexamethasone) is safe for patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Multiple Myeloma
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
Terminated
This phase II trial studies how well combination chemotherapy and inotuzumab ozogamicin work in treating patients with B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such a... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/03/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection
Terminated
Comparing two different corticosteroids (dexamethasone and triamcinolone) for use in sacroiliac joint injections
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/03/2024
Locations: Byron Schneider, Nashville, Tennessee
Conditions: Sacro-Iliac Spondylosis
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
Active Not Recruiting
The purpose of this study is to see whether pomalidomide (also known as Pomalyst) reduces the number of myeloma cells in the bones, and to see what is the best way to use pomalidomide in patients with myeloma. To do this, the investigators want to compare two types of treatment using pomalidomde. This is a randomized trial which means that the decision as to which treatment the patient will receive will be made by a computer, much like flipping a coin.
All patients start by receiving 4 cycles o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +9 locations
Conditions: Multiple Myeloma
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
Active Not Recruiting
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to individuals treated with standard chemotherapy.
Past studies conducted at the MIRT and at other institutions have shown that participants with high-risk features by gene array studies tend to have shorte... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Elimination of Minimal Residual Disease After Transplant
Recruiting
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Multiple Myeloma
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
Active Not Recruiting
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3).
Note: Randomization has been discontinued and accrual is closed to the L-TT3 arm. This trial is currently enrolling as a single-arm trial for patients to receive S-TT3.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2024
Locations: University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, Arkansas
Conditions: Multiple Myeloma
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Terminated
This phase II trial studies how well daratumumab-based therapy works in treating patients with newly diagnosed multiple myeloma with kidney failure. Daratumumab-based therapy includes daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib is a drug that prevents myeloma cells from getting rid of their waste products, leading to being targeted for death. Dexame... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Plasma Cell Myeloma, Renal Failure
Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity
Recruiting
This study is a single center, prospective, randomized, open-label study aimed at determining the most effective means of preventing hypersensitivity reactions in gynecologic oncology patients receiving paclitaxel infusions. The study will therefore provide clinicians with the best ways of preventing paclitaxel hypersensitivity reactions in their patients during treatment. Subjects will be randomized using the block randomization method into one of these three commonly used treatment methods:(1)... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Loma Linda University Cancer Center, Loma Linda, California
Conditions: Hypersensitivity Reactions
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Recruiting
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota +2 locations
Conditions: AL Amyloidosis
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Active Not Recruiting
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 monotherapy and CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Local Institution - 102, Scottsdale, Arizona +88 locations
Conditions: Multiple Myeloma
Exparel vs Block for ACL Reconstruction
Enrolling By Invitation
Liposomal bupivacaine or Exparel (Pacira Biosciences) is a long-lasting nonopioid analgesic that was initially utilized as an infiltrative agent but has more recently become U.S. Food and Drug Administration (FDA) approved for use in interscalene brachial plexus nerve blockade as well as infiltrative blockade. Delivery in this form is reported to provide up to 72 hours of extended-release bupivacaine. Exparel's use as a regional anesthetic has also become increasingly common and has shown promis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Rothman Orthopaedic Institute, Philadelphia, Pennsylvania
Conditions: ACL, Postoperative Pain
469 - 480 of 1455